ASTRAZENECA PLC

Read how AstraZeneca’s new EU approvals for Enhertu and Klygefa, plus FDA priority review for Efzimfotase Alfa, boost its oncology and rare‑disease pipeline—and why investors are watching closely.

Explore AstraZeneca’s latest clinical wins—COPD, lung, and breast‑cancer breakthroughs—and how they boost investor confidence and market value.

Tezspire’s Phase‑III win in eosinophilic esophagitis marks AstraZeneca’s breakthrough in rare‑disease therapy, boosting its growth prospects and dividend outlook.

EMA recommends AstraZeneca’s Datroway for metastatic triple‑negative breast cancer, boosting investor confidence and positioning it as the first TROP2‑directed therapy in Europe.

FDA approves AstraZeneca’s Truqap for PTEN‑deficient prostate cancer, marking the first targeted therapy for this rare subtype while priority review is granted to Ultomiris for IgA nephropathy, boosting AstraZeneca’s oncology and rare‑disease portfo…

Discover how AstraZeneca’s recent FDA approval of Imfinzi for bladder cancer and targeted anselamimab results reshape its oncology strategy and market outlook.

Explore how AstraZeneca’s May 2026 FDA approvals of BAXFENDY™ and Enhertu shape its market and oncology pipeline—and why shares slipped.

Discover AstraZeneca’s AI partnership with Owkin, breakthrough hypoparathyroidism drug results, and recent patent moves – all shaping the future of pharma.

Discover why Deutsche Bank upgraded AstraZeneca’s target to 11,500 GBp: a strong oncology pipeline, solid balance sheet and steady growth outlook make AZN a top pharma pick for investors.

Discover how AstraZeneca’s new U.S. biopharma leadership and Nasdaq‑100 exit sharpen growth focus and boost shareholder value.